Pantoprazole is a potent and selective proton pump inhibitor. It is an effective agent in the treatment of Peptic ulcers, Gastro-oesophageal reflux disease (GERD), Oesophagitis, Zollinger-Ellison syndrome and other GI hypersecretory disorders. It provides rapid symptoms relief up to 85-90% of Ulcer patients within 1 hour of treatment. It has mediocre bioavailability of 50% and poor aqueous solu...

Objective: The present study was an attempt to develop alternative dosage form for the existing conventional oral, parenteral proton pump inhibitor (PPI) as transdermal patches treating peptic ulcers. Methods: Transdermal of PPI were prepared using HPMC E5 with PVP K 30 and Eudragit L100 polymers in different ratios by a solvent evaporation method. All formulated subjected various evaluation pa...

The synthesis and characterization of solid complexes for pantoprazole sodium sesquihydrate (PNZ) with Cd(II), Hg(II) and Zn(II) metals in molar ratios M:L = 1:2 was studied. The complexes are stable in the solid state and are soluble only in DMF and DMSO. The metal complexes were characterized by elemental analysis, molar conductivity measurements, magnetic susceptibility, UV spectrophotometry...

T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor. Pantoprazole (PPZ) was identified to be a TOPK inhibitor from FDA-approved drug database by structure based virtual ligand screening. Herein, the data indicated that pantoprazole inhibited TOPK activ...

BACKGROUND Stress ulcer prophylaxis (SUP) using ranitidine, a histamine H2 receptor antagonist, has been associated with an increased risk of ventilator-associated pneumonia. The proton pump inhibitor (PPI) pantoprazole is also commonly used for SUP. PPI use has been linked to an increased risk of community-acquired pneumonia. The objective of this study was to determine whether SUP with pantop...

PURPOSE Limited drug distribution within solid tumors is an important cause of drug resistance. Basic drugs (e.g., doxorubicin) may be sequestered in acidic organelles, thereby limiting drug distribution to distal cells and diverting drugs from their target DNA. Here we investigate the effects of pantoprazole, a proton pump inhibitor, on doxorubicin uptake, and doxorubicin distribution and acti...

Objective: To discuss the role of a proton pump inhibitor (pantoprazole) as a cause of night sweats in an older person. Methods: Our case involves a 73 year-old man who experienced night sweats while taking pantoprazole to treat gastroesophageal reflux disease. Results: Night sweats disappeared ten days after ceasing pantoprazole. They recurred two months later, one week after recommencing pant...

BACKGROUND Short-term intravenous co-administration of famotidine and pantoprazole is used by some veterinarians to treat gastrointestinal bleeding in critically ill dogs. However, clinical studies have not evaluated the efficacy of combination acid suppressant treatment in dogs. HYPOTHESIS/OBJECTIVES To compare the effect of intravenous co-administration of famotidine and pantoprazole to mon...

Since the assay method for pantoprazole in pantoprazole pellets is not described in current pharmacopoeias (USP, BP), the aim of this work was to develop and validate a simple, precise and accurate method for determination of pantoprazole in pantoprazole pellets. Separation was achieved on a reversed-phase C8 column (250 x 4.6 mm i.d.; 5 a mixture of phosphate buffer pH 3.0 and acetonitrile as ...